PharmaMar

PharmaMar is a Madrid-based biopharmaceutical company with a focus on oncology, known for its commitment to research and development inspired by the sea to discover molecules with antitumor activity. The company is dedicated to providing healthcare professionals with innovative products to treat cancer. With a foundation established in 1986, PharmaMar has become one of the world leaders in the discovery of antitumor drugs of marine origin. The company has a pipeline of drug candidates and a robust R&D oncology program, including the development and commercialization of Yondelis® in Europe, as well as other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184, and PM14. PharmaMar also has subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States, along with full ownership of companies such as GENOMICA, a molecular diagnostics company, and Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). For more information about PharmaMar, please visit www.pharmamar.com.